| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-058 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于控股股东权益变动超过 1%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海润达医疗科技股份有限公司（以下简称"公司"或"润达医疗"）收到 控股股东杭州市拱墅区国有投资集团有限公司（以下简称"拱墅国投"）发来的 告知函，因2024年10月8日至2024年11月20日期间，公司可转债转股导致权益比 例被动稀释及拱墅国投接受的表决权委托股份减持，拱墅国投的权益发生变化， 现将有关情况公告如下： | 信息披露 义务人基 | 名称 住所 | 杭州市拱墅区国有投资集团有限公司 浙江省杭州市拱墅区绍兴路 号国投大厦 | | | 398 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-057 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 2024 年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2024 年 11 月 14 日 (二)股东大会召开的地点：上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 482 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 229,403,850 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 38.3048 | (四)表决方式是否符合《公司法》及《公司章程》的规定 ...

上海泽昌律师事务所 关于上海润达医疗科技股份有限公司 2024年第二次临时股东大会的 法律意见书 上海市浦东新区世纪大道 1589 号长泰国际金融大厦 11 层 电话：021-61913137 传真：021-61913139 邮编：200122 二〇二四年十一月 上海泽昌律师事务所 法律意见书 上海泽昌律师事务所 关于上海润达医疗科技股份有限公司 2024 年第二次临时股东大会的 法律意见书 泽昌证字 2024-01-02-08 致：上海润达医疗科技股份有限公司 上海泽昌律师事务所（以下简称"本所"）接受上海润达医疗科技股份有限公 司（以下简称"公司"）委托，就公司召开 2024 年第二次临时股东大会（以下 简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）中国 证券监督管理委员会发布的《上市公司股东大会规则》（以下简称"《股东大会 规则》"）等法律、法规、规章和其他规范性文件以及《上海润达医疗科技股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to recover its main business, with advancements in AI applications across multiple fields in the medical sector [1] - The company reported a revenue of 6.176 billion yuan for the first three quarters of 2024, a year-on-year decrease of 10.36%, and a net profit attributable to shareholders of 504.2 million yuan, down 82.21% year-on-year [1] - The third quarter performance was slightly pressured due to weak consumer demand and other factors, with a revenue of 2.041 billion yuan, a year-on-year decline of 13.85%, and a net profit of 408.8 million yuan, down 137.6% year-on-year [1] Financial Performance Summary - The company is projected to achieve total revenue of 9.147 billion yuan in 2023, with a year-on-year decrease of 12.8%, and is expected to recover to 9.32 billion yuan in 2024, reflecting a growth of 1.9% [2][6] - The net profit attributable to shareholders is forecasted to be 273 million yuan in 2023, down 34.6%, and is expected to recover to 259 million yuan in 2024, a decrease of 5.3% [2][6] - The gross margin is projected to be 26.6% in 2023, slightly decreasing to 26.3% in 2024, and expected to improve to 29.7% by 2026 [2][6] Strategic Developments - The company has launched several AI-driven initiatives, including the "CDx Liangyi Xiaohui" medical model and partnerships with Huawei Cloud and other organizations to enhance healthcare services [1] - Collaborations with various partners aim to innovate in health management and improve service quality, such as the strategic cooperation with China Mobile in Harbin to advance smart healthcare [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to recover its main business, with advancements in AI applications across multiple fields in the medical sector [1] - The company reported a revenue of 6.176 billion yuan for the first three quarters of 2024, a year-on-year decrease of 10.36%, and a net profit attributable to shareholders of 504.2 million yuan, down 82.21% year-on-year [1] - The third quarter performance was slightly pressured due to weak consumer demand and other factors, with a revenue of 2.041 billion yuan, a year-on-year decline of 13.85%, and a net profit of 408.8 million yuan, down 137.6% year-on-year [1] Financial Performance Summary - The company is projected to achieve total revenue of 9.147 billion yuan in 2023, with a year-on-year decrease of 12.8%, and is expected to recover to 9.32 billion yuan in 2024, reflecting a growth of 1.9% [2][6] - The net profit attributable to shareholders is forecasted to be 273 million yuan in 2023, down 34.6%, and is expected to recover to 259 million yuan in 2024, a decrease of 5.3% [2][6] - The gross margin is projected to be 26.6% in 2023 and slightly decrease to 26.3% in 2024, with an expected increase to 29.7% by 2026 [2][6] Cash Flow and Investment Activities - The operating cash flow is expected to be 730 million yuan in 2024, increasing to 912 million yuan in 2025 [4] - The company anticipates capital expenditures of 297 million yuan in 2024, decreasing to 244 million yuan by 2026 [4] Strategic Developments - The company has launched several AI medical applications, including a health management program in collaboration with Huawei Cloud and a smart pharmacy upgrade plan with Liuyao [1] - A strategic cooperation agreement was signed with China Mobile to enhance smart medical development in Harbin [1]

| 股东 | 是否为 控股股 | 本次质押股 | 是否 为限 | 是否补 | 质押 | 质押 | 质权 | 占其所 持股份 | 占公司总 股本比 | 质押融 资资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 数 | | 充质押 | 起始日 | 到期日 | 人 | | | | | | 东 | | 售股 | | | | | 比例% | 例% | 用途 | | 朱文 怡 | 否 | 10,460,000 | 否 | 否 | 2023.10.19 | 2025.10.17 | 中信 建投 | 33.19% | 1.75% | 个人 需要 | | | | 80,000 | | 是 | 2024.11.08 | | | 0.25% | 0.01% | | | 合计 | / | 10,540,000 | / | / | / | / | / | 33.44% | 1.76% | / | 一、本次股份质押基本情况 本次质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他保障用途。 朱文怡女士持有公司股份 3 ...

会 议 材 料 【二零二四年十一月】 上海润达医疗科技股份有限公司 资料目录 上海润达医疗科技股份有限公司 2024 年第二次临时股东大会 现场会议时间：2024 年 11 月 14 日（星期四）13:30； 网络投票时间：2024 年 11 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00； 现场会议地点：上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼； 会议主持人：董事长张诚栩先生。 | 一、2024年第二次临时股东大会议程--------------------------------------------1 | | --- | | 二、会议注意事项----------------------------------------------------------------------2 | | 三、审议事项 | | 议案一：关于全资子公司为公司发行公司债券提供反担保的议案 1. | | -- ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-055 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 注 4：武汉优科的少数股东将合计 40.54%股份质押给公司以承担其持股比例的担保责任，公司实际承担 51%的担保责任； 一、担保情况概述 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2023 年度股东大会审议通过：自 2024 年 5 月 23 日至 2024 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 421,300 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：三家 ...

Revenue and Profitability - Revenue for the third quarter decreased by 13.84% year-over-year, with total revenue reaching 6,176,286,324.36 RMB, a year-to-date decrease of 10.36%[2] - Net profit attributable to shareholders of the listed company dropped by 137.69% year-over-year for the third quarter, with a year-to-date net profit of 50,424,910.92 RMB, down 82.21%[2] - Total operating revenue for the first three quarters of 2024 was RMB 6,176,286,324.36, a decrease of 10.36% compared to RMB 6,890,332,466.40 in the same period of 2023[18] - Net profit attributable to the parent company's shareholders for the first three quarters of 2024 was RMB 50,424,910.92, a significant decrease of 82.21% compared to RMB 283,453,202.57 in the same period of 2023[22] - Revenue for the first three quarters of 2024 was RMB 1,294,991,244.54, a decrease of 42.1% compared to RMB 2,235,857,829.07 in the same period of 2023[29] - Operating profit for the first three quarters of 2024 was RMB 8,261,138.58, a significant drop from RMB 176,006,091.97 in the same period of 2023[30] - Net profit for the first three quarters of 2024 was RMB 14,557,299.52, compared to RMB 180,107,764.21 in the same period of 2023[30] Earnings Per Share (EPS) - Basic earnings per share (EPS) for the third quarter were -0.07 RMB, a decrease of 136.84% year-over-year[3] - Basic earnings per share for the first three quarters of 2024 were RMB 0.08, down 83.67% from RMB 0.49 in the same period of 2023[23] - Basic earnings per share for the first three quarters of 2024 were RMB 0.02, down from RMB 0.31 in the same period of 2023[30] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were RMB 4,592,846,859.28, down 10.11% from RMB 5,109,831,024.35 in the same period of 2023[18] - The company's operating costs did not decrease proportionally with revenue, further affecting profitability[8] - R&D expenses for the first three quarters of 2024 were RMB 81,276,813.53, a decrease of 21.22% compared to RMB 103,178,932.82 in the same period of 2023[18] Cash Flow and Liquidity - Operating cash flow for the year-to-date increased by 12.99% to 208,487,607.14 RMB[2] - Cash received from sales of goods and services in the first three quarters of 2024 was RMB 7,406,130,055.09, a slight decrease of 2.14% from RMB 7,568,518,985.69 in the same period of 2023[24] - Cash paid for goods and services in the first three quarters of 2024 was RMB 5,741,070,855.72, a slight decrease of 0.79% from RMB 5,786,996,990.39 in the same period of 2023[24] - Operating cash flow increased to 208,487,607.14 in Q3 2024, up from 184,520,267.81 in the previous period[25] - Net cash flow from financing activities turned positive at 51,465,972.24, compared to a negative -155,375,513.39 in the previous period[25] - Cash flow from operating activities for the first three quarters of 2024 was negative RMB 392,081,178.64, compared to positive RMB 241,511,156.96 in the same period of 2023[31] - Cash flow from investing activities for the first three quarters of 2024 was positive RMB 179,301,515.47, an increase from RMB 80,568,694.77 in the same period of 2023[31] - Cash flow from financing activities for the first three quarters of 2024 was positive RMB 230,642,952.33, compared to negative RMB 339,602,272.39 in the same period of 2023[31] - Total cash and cash equivalents at the end of the third quarter of 2024 were RMB 78,637,754.89, up from RMB 43,935,410.87 at the end of the same period in 2023[31] Assets and Liabilities - Total assets as of the end of the reporting period were 14,361,164,907.93 RMB, a slight increase of 0.36% compared to the end of the previous year[3] - Total assets grew to 8,496,828,306.32 as of September 30, 2024, up from 8,068,649,586.26 at the end of 2023[26] - Accounts receivable decreased to 1,139,809,345.70, down from 1,320,810,853.41 at the end of 2023[26] - Prepayments increased significantly to 1,414,438,728.31, more than double the 582,237,837.82 at the end of 2023[26] - Inventory decreased to 190,664,144.26, down from 383,639,633.70 at the end of 2023[26] - Total liabilities increased to 5,695,303,704.12, up from 5,241,745,365.60 at the end of 2023[27] - Short-term borrowings rose to 1,573,886,915.14, up from 1,324,854,032.14 at the end of 2023[27] - Equity decreased slightly to 2,801,524,602.20, down from 2,826,904,220.66 at the end of 2023[28] - Retained earnings decreased to 681,298,404.98, down from 726,627,397.66 at the end of 2023[28] Non-Recurring Items and Government Subsidies - Non-recurring gains and losses for the period amounted to 5,766,516.18 RMB, with government subsidies contributing 6,750,451.40 RMB[4][5] Credit Impairment and Investment Income - The company's gross margin remained relatively stable, but credit impairment losses increased significantly compared to the same period last year, impacting net profit[6] - Historical payment cycles from some hospital customers have lengthened, contributing to higher credit impairment losses[6] - Credit impairment losses for the first three quarters of 2024 were RMB -112,898,735.77, an increase of 66.94% compared to RMB -67,614,867.79 in the same period of 2023[18] - Investment income for the first three quarters of 2024 was RMB 97,818,515.41, a decrease of 48.59% compared to RMB 190,288,942.37 in the same period of 2023[18] Business Expansion and Costs - The company has been investing in new business expansion, leading to increased marginal costs[6] Comprehensive Income - Total comprehensive income for the first three quarters of 2024 was RMB 144,214,102.93, down 64.92% from RMB 411,095,919.44 in the same period of 2023[23]

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-051 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 董事会决议公告 二、董事会会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于审议公司2024年第三季度报告的议案》。 2024 年第三季度报告详见同日刊登在上海证券交易所网站（www.sse.com. cn）及《中国证券报》、《上海证券报》、《证券日报》、《证券时报》。 本议案已提交董事会审计委员会全票审议通过。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 （二）审议通过了《关于全资子公司为公司发行公司债券提供反担保的议 案》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海润达医疗科技股份有限公司（以下简称"公司"）第五届董事会第十七次 会议通知于2024年10月24日以邮件形式发出，会议于2024年10月28日（星期一） 15: ...